The most common question users ask after starting an IGF-1 LR3 cycle: "When am I supposed to feel something?"
Research-context information only. IGF-1 LR3 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
The honest answer: the published research base for LR3 IGF-1 is almost entirely animal data, and the human clinical record for the analog used at community doses is essentially blank. What follows pulls together what the animal literature documents at specific time points, what community protocols report across the standard 10-day on / 4-week off pattern, and where the two sources agree or diverge.
This is a reporting article — it covers what has been documented, not what should be done. Expect a more conservative timeline than community marketing tends to suggest.
Table of Contents
- What "Results" Actually Means With IGF-1 LR3
- Week-by-Week Timeline (Standard 10-Day Cycle)
- Multi-Cycle Patterns (3-6 Months)
- Biomarker Watch: What Studies and Community Monitoring Track
- What Determines Where Results Land in the Range
- What Does NOT Typically Happen
- Related Reading
- References
What "Results" Actually Means With IGF-1 LR3
Three context points before any week-by-week breakdown:
1. The dosing window is short. The most commonly referenced community protocol is 50 mcg per day for 10 consecutive days, followed by 4 weeks off (see dosing guide). That is a 10-day exposure window, not a continuous cycle. Compared to peptides that are run for 8-12 weeks, the active window is a fraction of that.
2. The half-life outlasts the injection. LR3 IGF-1 binds poorly to IGF binding proteins (IGFBPs), giving it a circulating half-life of roughly 20-30 hours versus minutes for native IGF-1 (Tomas et al., 1993). Each daily injection layers on top of the previous, so plasma levels build through the 10-day window and tail off after the last dose.
3. Most "results" are signaling, not visible. Animal studies show LR3 IGF-1 increases body weight gain, nitrogen retention, and food conversion efficiency (Tomas et al., 1993) and suppresses muscle protein degradation pathways within an hour (Sacheck et al., 2004). These are the changes that drive eventual physique shifts. The visible part — pump, fullness, scale weight — lags the molecular activity by days to weeks.
With those caveats in place, here is what the data and community sources describe at each phase.
Week-by-Week Timeline (Standard 10-Day Cycle)
Days 1-3: Loading Phase — Mostly Subjective
The first 2-3 days of a 10-day cycle are when plasma LR3 IGF-1 is climbing toward steady-state. Animal data shows the molecular changes happen fast — atrogin-1 mRNA suppression within 1 hour of IGF-1 exposure (Sacheck et al., 2004) — but the visible/subjective changes lag.
What animal models and community sources describe:
- Anti-catabolic signaling activates within hours. Sacheck et al. demonstrated that IGF-1 reduced atrogin-1 expression within 1 hour by blocking mRNA synthesis, with MuRF1 suppression following more gradually. Both are E3 ubiquitin ligases that drive muscle protein breakdown (Sacheck et al., 2004).
- Mild hypoglycemic awareness. Community reports during the first 2-3 days frequently describe lightheadedness or shakiness if injections are timed away from food. This is the most reproducible early signal users describe and is consistent with IGF-1's insulin-like activity.
- Possible appetite shift. Some users self-report increased hunger; others describe no change. Animal data on food conversion efficiency suggests calories are partitioned more aggressively toward lean tissue (Tomas et al., 1993), but appetite responses are variable.
What is unlikely at this stage: Visible muscle changes, scale weight gain, or measurable strength shifts. Users who expect dramatic early visual changes typically describe disappointment in this window.
Community starting-dose pattern: A subset of community protocols use 20 mcg for the first 2-3 days to assess hypoglycemia response before stepping up to 50 mcg. This is reported as a tolerance check, not a therapeutic loading strategy.
Days 4-7: Peak Window
By day 4-5, plasma LR3 IGF-1 has accumulated across multiple half-lives. Animal data on continuous LR3 infusion shows organ-level effects emerge in this window — Bastian et al. measured significantly increased fractional weights of adrenals, gut, kidneys, and spleen after just 7 days of LR3 IGF-1 infusion in guinea pigs (Bastian et al., 1995).
What community sources most consistently report:
- Muscle fullness and pump. The most reproducible subjective signal. Trained muscles feel rounder and more vascular during and immediately after training. This pattern is reported across forums and is consistent with IGF-1's known effects on intracellular hydration and protein synthesis through PI3K/Akt/mTOR (Yoshida & Delafontaine, 2020).
- Improved training output. Some users describe modestly higher work capacity — extra reps at the same load, faster between-set recovery. This is anecdotal and not supported by controlled human trials specific to LR3.
- Weight changes are usually water/glycogen. Scale weight typically rises 1-3 lbs in this window. Animal data confirms increased nitrogen retention with LR3 IGF-1 (Tomas et al., 1993), but most of the visible scale movement during a 10-day cycle reflects increased intracellular water and glycogen rather than new contractile protein.
Hypoglycemia awareness peaks here. Community reports describe the days 4-7 window as the period of greatest blood-sugar awareness, with several users describing the need for fast carbs on hand. This is consistent with IGF-1's insulin-like activity at the IGF-1 receptor and at insulin receptors at higher concentrations.
Days 8-10: Final Doses + Trailing Effects
The last three injections layer onto an already-elevated plasma level. Animal data on LR3 infusion in pigs showed continued suppression of plasma growth hormone (~23% decrease) and IGFBP-3 across the 4-day infusion window (Tomas et al., 1997) — by days 8-10 of a 10-day human community protocol, this kind of HPG-axis suppression would be expected to be active.
What community sources describe:
- Sustained pump and fullness. Most consistent peak window of the cycle.
- Scale weight stabilizing. Most weight gain (water + glycogen) has occurred by this point. Continued weight gain is uncommon within a single 10-day window.
- Mild fatigue or lethargy in some users. Reported variably. Mechanism is unclear; speculation includes endogenous IGF-1 axis suppression or downstream insulin/glucose dynamics.
End of injection schedule: The last injection on day 10 still produces 20-30 hours of meaningful plasma activity. Effects do not abruptly stop on day 11.
Days 11-14: Tail-Off and Early Washout
The first 3-4 days after the last injection are not "off-cycle" in any biological sense. LR3 IGF-1 from the day-10 dose is still active for the first day, and the downstream protein-synthesis signaling continues for some period after.
What animal and community sources suggest:
- Continued anabolic carryover. The intracellular signaling cascades activated during dosing — PI3K/Akt/mTOR for synthesis, FoxO suppression for anti-catabolism — do not terminate immediately when plasma LR3 clears (Yoshida & Delafontaine, 2020).
- Some community users describe their best gym sessions in this window. Glycogen stores are full, fullness is still present, and recovery feels enhanced. This is anecdotal.
- Endogenous IGF-1 is suppressed. In the pig data, plasma IGF-1, IGFBP-3, and growth hormone were all reduced by LR3 infusion (Tomas et al., 1997). Recovery of the natural axis takes time and is one of the rationales for the 4-week off period.
Weeks 3-4: Post-Cycle Washout
By 2-4 weeks after the last injection, plasma LR3 has long cleared, and the body is restoring its own IGF-1 production. This is when community sources describe the most honest assessment of "what the cycle did."
What sources describe:
- Most water/glycogen weight has dropped. Scale weight typically settles 1-3 lbs above pre-cycle baseline if any retention occurred.
- Strength sometimes plateaus or regresses slightly. Without continued anabolic signaling, training stimuli must drive any maintained gains. Users without consistent training programs frequently describe losing what they thought they gained.
- Sleep, appetite, and energy normalize. Hypoglycemia awareness fades. Endogenous GH and IGF-1 axis recovery is in progress but not necessarily complete at 4 weeks.
The 4-week off-cycle is a recovery period, not a maintenance period. Animal data showing endogenous IGF-1 suppression during LR3 use (Bastian et al., 1995; Tomas et al., 1997) is the basis for keeping the off-period at least 3-4x longer than the on-period.
Ready to buy? Compare verified vendors on our best IGF-1 LR3 sources page, or browse all coupon codes for up to 50% off.
